$527K in expenses

Research and drug development:in 2024, the glioblastoma foundation advanced its research mission by acquiring lisavanbulin, a promising targeted therapy from basilea pharmaceutica, for further clinical development in glioblastoma. This acquisition marked a critical step toward bringing patients new, more effective treatments. The foundation also supported investigator-initiated research on molecular characterization and functional precision oncology. Additionally, the foundation established gliolab, a clia-registered genomic laboratory that will provide state-of-the-art testing to accelerate discovery of targeted therapies based on each tumor's genomic and epigenomic profile.

$527K in expenses

Patient support and education:throughout 2024, the foundation provided support services for glioblastoma patients and caregivers nationwide, including personalized clinical-trial matching, professionally led virtual support groups, and educational resources on treatment options and emerging research. These programs empowered patients to make informed care decisions and fostered a sense of community among families affected by this rare disease. Hundreds of patients and caregivers benefited from these free services during the year.

$527K in expenses

Public awareness and advocacy:the foundation led nationwide efforts to raise awareness and advocacy for those affected by glioblastoma. In 2024, it organized glioblastoma awareness day and continued the voices of glioblastoma podcast while planning to expand the series in future years to feature additional patient, caregiver, and scientist perspectives. The foundation also partnered with events such as the los angeles marathon to increase public understanding and support for research. These initiatives educated thousands and inspired hope within the glioblastoma community.